NDAINTRAVENOUSPOWDERPriority Review
Approved
Feb 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Mechanism of Action
4 and 6. Hematopoietic stem and progenitor cells (HSPCs) in the bone marrow give rise to circulating neutrophils, RBCs, and platelets. HSPC proliferation is dependent on CDK4/6 activity.
Clinical Trials (2)
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
Started Jan 2024
36 enrolled
Metastatic Triple-Negative Breast Cancer
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
Started Jun 2017
107 enrolled
Small Cell Lung Cancer
Loss of Exclusivity
LOE Date
Nov 13, 2040
178 months away
Patent Expiry
Nov 13, 2040
Exclusivity Expiry
Feb 12, 2026